Covidien kicks off PAD studies in Europe
Covidien plc (NYSE:COV) has begun enrolling patients in three studies at Belgian hospitals utilizing treatments for peripheral arterial disease (PAD), according to the Dublin-based company that has U.S. headquarters in Mansfield.
Covidien said its Definitive AR anti-restenosis study is enrolling patients at Imelda Hospital in Bonheiden, Belgium. Definitive AR is a pilot study designed to address restenosis, which is the narrowing of a blood vessel in patients with PAD, and will look at the impact of treating a diseased vessel with plaque excision prior to the use of a drug-coated balloon. The study will focus on whether removing calcified plaque will enhance the absorption of drugs delivered by a drug-coated balloon.